

# Basis of reporting 2025: Environmental data

GSK report against the following metrics for all sites under operational control as defined in our organisational boundary approach. Our reporting period covers 01 January to 31 December. GSK use December prior year as a proxy for December current year where data is not available. GSK's baseline year for its environmental targets is 2020. These environmental metrics were selected from the materiality assessment completed in 2021 and our published targets towards our net zero and nature positive ambition where indicators are available.

Reported environmental metrics are:

Sub-metric	Scope
<b>Absolute greenhouse gas emissions (GHG) from emissions (tCO<sub>2</sub>e which is converted to thousand tonnes CO<sub>2</sub>e for ease of reading)</b>	
Scope 1	Emissions from onsite fuel use Emissions from sales force vehicles Fugitive emissions of fluorinated gases (refrigerant losses, propellant losses)
Scope 2	Generation of purchased electricity following both market and location-based accounting Generation of purchased heat/steam, cooling and compressed air
Scope 3	Category 1: Purchased goods and services Category 2: Capital goods Category 3: Fuel- and Energy-Related Activities (Transmission Losses) Category 4: Upstream Transportation and Distribution Category 5: Waste Generated in Operations Category 6: Business Travel Category 7: Employee commuting and working from home Category 9: Transportation and distribution (downstream) Category 11: Use of sold products Category 12: End of life Category 15: Investments
<b>Scope 1 &amp; 2 GHG emissions intensity from energy</b>	
per £m revenue	
per full time equivalent (FTE)	
<b>Energy (GWh)</b>	
Total energy for Operations % Renewable electricity	Natural gas purchased, electricity used, exported electricity, coal, other fossil fuels, renewable heat, purchased heating and cooling, purchased non-renewable electricity, purchased renewable electricity, on-site renewably generated electricity. The amount of energy exported back to the grid is removed from this total.
<b>Industrialisation of low GWP Metered Dose Inhalers</b>	
Industrialisation of low GWP Metered Dose Inhalers initiated with clinical and non-clinical data available to support regulatory submissions.	
<b>% MTCO<sub>2</sub> of 2030 carbon credits volume in project pipeline</b>	
Volume of carbon credits secured in the portfolio is as a percentage of GSK emissions value in 2030 .	
<b>Water (recorded as m<sup>3</sup> and converted to million m<sup>3</sup>)</b>	
Total Water Use	Supplied water from municipal, ground water, and tankers. Water at high-risk sites and recycled sources.
Total wastewater discharged	To municipal sewer, surface water, land and others.
% of GSK Sites and Supplier Locations used by GSK that are compliant with AMR Alliance and Wastewater API limits	The percentage of in scope GSK sites and suppliers handling, manufacturing, or using APIs in compliance with AMR Alliance and waste-water API limits or that have corrective and preventive actions (CAPAs) in place.
<b>Waste (metric tonnes converted to thousand tonnes)</b>	
Total waste generated	Total waste recovered via a circular route Total waste disposed via a non-circular route
% circular waste	% of waste generated going into circular route
Total hazardous waste	Total hazardous waste recovered via a circular route Total hazardous waste disposed via a non-circular route
Total non-hazardous waste	Total non-hazardous waste recovered via a circular route Total non-hazardous waste disposed via a non-circular route
Total waste incinerated	Total hazardous waste incinerated Total non-hazardous waste incinerated
Total waste to landfill	Total hazardous waste to landfill Total non-hazardous waste to landfill
<b>Biodiversity and sustainable sourcing</b>	
% of paper and palm oil certified	

Note: Calculation methodologies for reported metrics are in Appendix 1. Ozone-depleting substances (kg of CFC11e) are no longer reported on grounds of materiality. GSK have reduced our inventory of hydrochlorofluorocarbon (HCFC) refrigerants, which deplete the ozone layer, to below reportable levels. This inventory is expected to be eliminated within the next two years as remaining equipment containing HCFCs becomes obsolete.

## Scope of reporting

### Organisational boundary

Environmental data is collected for facilities owned or leased by GSK and its joint venture partners over which GSK has full operational control. Any facilities that are not managed or operated by GSK are not required to report. Divestments or site closures are removed from scope from the date of divestment or notification of ceasing routine operations. In alignment with the GHG Protocol, site closures are not retrospectively removed from the data. Acquisitions, as aligned with the reporting boundary, will come into scope the following year, after review and update of the controlled real estate database.

Routine, for the purpose of reporting, relates to the regular manufacturing and R&D processes and activities conducted in the discovery, design, development, and manufacture of medicines. Routine excludes activities not linked to such processes and activities, including, but not limited to, construction, decommissioning and demolition of facilities and gardening activities.

All GSK locations, either owned or leased are required to report energy, water, and waste data if any of the following criteria are met:

- The total energy usage >4,750MWh per annum or
- the total water in is > 10,000 m3 per annum or
- total waste generated >250 tonnes per annum

In 2020, baseline year, GSK set a De Minimis threshold to ensure over 95% of environmental impacts from energy, water, and waste are reported. Annually, if this threshold is not met through individual site reported data, an estimate based on the next largest sites' square footage will be added to the year-end total for the relevant environmental impacts.

### Reporting standards and frameworks

GSK report a range of greenhouse gas emissions across Scope 1, 2 and 3, water, waste, and biodiversity indicators. GSK align to the Greenhouse Gas Protocol Corporate Standard for Scope 1 and 2 carbon emissions reporting<sup>1,2</sup>. For scope 3 emissions GSK align to Greenhouse Gas Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard<sup>3</sup>. Operational impacts such as energy, water use, wastewater, waste, and scope 1&2 GHG emissions are reported at site level, except for the impact of the sales fleet which is an operational impact that is reported at a global level. GSK have

identified key suppliers annually for reporting of Anti-Microbial Resistance (AMR) and Active Pharmaceutical Ingredients (API) wastewater impacts in the supply chain.

### Emissions factors

GSK measures and reports emissions arising from four of the main greenhouse gases that contribute to climate change, namely carbon dioxide (CO<sub>2</sub>), methane (CH<sub>4</sub>), nitrous oxide (N<sub>2</sub>O), and hydrofluorocarbons (HFCs). Perfluorocarbon (PFC) and Nitrogen trifluoride (NF<sub>3</sub>) are excluded on the basis that GSK do not use PFCs or NF<sub>3</sub>. Emissions from the greenhouse gasses (SF<sub>6</sub>) were evaluated in 2024 based on the number of fume hoods and considered not material and excluded for further reporting.

The effect of these emissions is reported as a single figure, carbon dioxide equivalent (CO<sub>2</sub>e), which represents their combined global warming potential (GWP). To get a meaningful comparison between the GHG emissions, conversion factors are used to convert the quantities consumed into tonnes of carbon dioxide equivalent (tCO<sub>2</sub>e). CO<sub>2</sub>e is a measure for describing the impact of each different GHG in terms of the amount of carbon dioxide that would create the same amount of global warming. Emission factors are sourced from the following organisations for application across GSK. These are updated annually. Emission factor details are included in Appendix 2.

- The International Energy Agency annual GHG emission factors for world countries from electricity and heat generation
- UK Government conversion factors for company reporting of greenhouse gas emissions<sup>4</sup> published annually by the Department for Energy Security and Net Zero.
- International Panel on Climate Change (IPCC) 4th Assessment Report<sup>5</sup>
- From 2021 onwards individual vehicle fuel emissions factors are supplied by fleet management providers

### Energy conversion factors

Fuel calorific factors are used to convert fuel data that is reported in volumetric or mass units by sites. These are taken from UK Government conversion factors for company reporting of greenhouse gas emissions<sup>6</sup>.

<sup>1</sup>GHG Protocol Corporate Accounting and Reporting Standard 2015 edition, <https://ghgprotocol.org/corporate-standard> last accessed 16 December 2025

<sup>2</sup> Scope 2 Guidance 2015 edition, <https://ghgprotocol.org/scope-2-guidance> last accessed 16 December 2025 [corporate-standard](https://ghgprotocol.org/corporate-standard) last accessed 16 December 2025

<sup>3</sup> Corporate Value Chain (Scope 3) Accounting and Reporting Standard 2011 edition <https://ghgprotocol.org/corporate-value-chain-scope-3-standard> last accessed 16 December 2025

<sup>4</sup> <https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting> last accessed 16 December 2025

<sup>5</sup> AR4 Climate Change 2007: The Physical Science Basis, table 2.14, P212, Chapter 2, Global warming potential for 100 year, <https://www.ipcc.ch/assessment-report/ar4/> [https://www.ipcc.ch/site/assets/uploads/2018/05/ar4\\_wg1\\_full\\_report-1.pdf](https://www.ipcc.ch/site/assets/uploads/2018/05/ar4_wg1_full_report-1.pdf) last accessed 16 December 2025

<sup>6</sup> <https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting> last accessed 16 December 2025

---

# Data Management

## Data Collection and Documentation

Data that forms the basis of reporting was obtained from financial reporting systems, accounts payable records, other internal records, outside sources such as fleet management companies, utilities providers, and proprietary databases. GSK sites within the reporting boundary report energy use, supplied water, waste, wastewater, non-energy related Scope 1 emissions data, or to identify when a site has a maintenance shut down event. Reported selected Scope 3 emissions data, and selected water quality data into a single data is verified to ensure it follows 'Data Standard - Sustainability Performance Indicators (SPI)'. While the description in this document is intended to be as accurate as possible, invariably, the inventory will contain some exceptions to this reporting basis. This might also include sites in areas of operation where due to extenuating circumstances data is not fully available (such as conflict or natural disasters).

Data is entered or collated either monthly, quarterly, or annually depending on the source information and detailed in the relevant metric calculation methodology. Source data used for environmental metrics comes from a variety of inputs such as, utility invoices, meter readings, waste transfer notes, financial systems, supplier contracts, or site control systems.

Scope 3 greenhouse gas emissions data is collected one year in arrears, so data reported in the current reporting year is from the prior year, except for patient use of Metered Dose Inhalers which is calculated from production of MDIs in calendar reporting year.

As with previous years, reported figures include estimates or assumptions where actual data is unavailable. Estimates are based on historical data, spend data or other proxies as identified in the calculation methodology (Appendix 1).

The values are rounded for all reported numbers. For quantitative data points, decimal places will be consistent with the prior year; if there is no precedent, two decimal places are used. Percentage (%) values are rounded to the nearest percentage point.

## Data Changes and Governance

Environmental indicator fields have controls applied which trigger the need for a comment to be reported in the database if a tolerance of +/- 25% is exceeded compared to the previously reported value. This control identifies gross input errors such as incorrect unit of measures being used, or to identify when a site has a maintenance shut down event. Reported data is verified to ensure it follows 'Data Standard - Sustainability Performance Indicators (SPI)'. While the description in this document is intended to be as accurate as possible, invariably, the inventory will contain some exceptions to this reporting basis. This might also include sites in areas of operation where due to extenuating circumstances data is not fully available (such as conflict or natural disasters).

GSK will restate the baseline year 2020 emissions or subsequent years emissions data in the event of a material structural change such as the demerger of an entire business unit. Historic data is restated where material changes (defined as >5% of total reported environmental metric) are made due to data improvements (e.g., refined estimation or calculation methodologies). GSK will not restate the baseline or subsequent years for smaller changes such as the closure of a manufacturing site or the divestment of a brand of products, but commentary may be provided in the narrative.

Monthly dashboards of key indicators are shared with business unit sustainability leads and quarterly performance reviews at the GSK Sustainability Council. There are additional business unit Councils to review specific environmental metrics and performance plans. The overall GSK environmental governance is set out in the Annual Report.

---

## Key terms

GSK refer to a series of terms across the Responsible Business report to reflect the environmental ambition and direction.

Term	Definition
Net zero impact on climate	Net zero emissions means, reducing Scope 1, 2 and 3 emissions as much as is practicable in line with climate science to maintain global temperature increases below 1.5°C, and then balancing the remaining residual emissions through carbon removal credits. GSK's carbon reduction plan is available on <a href="https://www.gsk.com">gsk.com</a>
Contributing to a nature positive world	Contributing to a nature positive world for GSK means reducing environmental impacts across freshwater, land, ocean, biodiversity, waste and materials and investing in nature protection and restoration. Explained in GSK Biodiversity Strategy and GSK nature plan available on <a href="https://www.gsk.com">gsk.com</a>
Zero operational waste	We define zero operational waste as a 20% reduction in operational waste and 100% operational waste circularity, including zero waste to landfill
Environmental impact reduction of products and packaging	We implement product and packaging interventions that contribute to our company level targets across the portfolio. As a lead metric, we measure the aggregated carbon reduction, in %, delivered on the 12 products including packaging that are anticipated to be the main drivers of the 2030 company carbon footprint if no eco-design action was taken <sup>7</sup> .
Waste reduction from supply chain	Waste accumulates along the supply chains of purchased materials. To reduce generation of this waste, we implement material efficiency projects, move to the use of lower impact materials, and help our supply chain switch from fossil to renewable energy. We measure the resulting waste reduction through application of LCA based 'cradle to gate' wastage rates and waste reduction factors.

---

---

<sup>7</sup> [https://green-forum.ec.europa.eu/green-business/environmental-footprint-methods\\_en#:~:text=The%20Environmental%20Footprint%20methods%20measure%20and%20communicate%20about,scientifically%20sound%20assessment%20methods%20agreed%20at%20international%20level](https://green-forum.ec.europa.eu/green-business/environmental-footprint-methods_en#:~:text=The%20Environmental%20Footprint%20methods%20measure%20and%20communicate%20about,scientifically%20sound%20assessment%20methods%20agreed%20at%20international%20level)

Last accessed 16 December 2025

## Climate Related Reporting

GSK sites report all purchased energy such as grid electricity, natural gas, diesel, other fuels, and on-site renewable energy such as hot water, electricity and heat generated from solar, wind or biomass into a central database in units of energy or volume. Data is reported by energy type based on invoice data or meter readings. Energy is converted into kWh for reporting purposes using fuel calorific values taken from the UK Government conversion factors for greenhouse gas reporting.

Purchased renewable electricity is renewable electricity generated by a supplier that is purchased under a supply agreement that includes evidence of origin such as REC, REGOs or as part of a Power Purchase Agreement (PPA). Renewable heat is heat generated from the combustion of a biofuel such as wood biomass. Energy values are reported internally in kilowatt hours (kWh) and converted to GWh for external reporting, except where noted.

## Scope 1 and 2 carbon emissions

Reported Metric and KPI	Definition and scope	Source and calculated methodology (converted to GWh for external reporting)
Natural gas purchased	Energy from the combustion of purchased natural gas	Natural gas consumption data is reported by sites in local units of energy (kWh, GJ, decatherm, mmBTU etc) or volume (m <sup>3</sup> , HCF, CCF etc). Data reported in volumetric units are converted to kWh.
Other fossil fuels	Energy from the combustion of purchased diesel/light fuel oil, heavy fuel oil, LPG, and solvent use for onsite energy recovery	<p>Diesel, fuel oil, LPG, and solvent (used for onsite energy recovery) consumption data is reported into GSK's reporting database by sites in local units of energy (kWh, GJ, dekatherm, mmBTU etc) or volume (l, m<sup>3</sup>, HCF, CCF etc). Data reported in volumetric units are converted to kWh.</p> <p>Sites report the value based on one of the following single methods throughout the year:</p> <ul style="list-style-type: none"> <li>Tank level readings</li> <li>Flow meter readings or</li> <li>Invoices</li> </ul> <p>It is assumed that diesel fuel purchased during the fiscal year is used that year. This method likely overestimates actual emissions in some years and underestimates them in others but, over time, captures the related emissions.</p>
Biomass fuels	CH <sub>4</sub> and NO <sub>x</sub> gases released during the combustion of biomass	Scope 1 carbon emissions from the combustion of biomass consider that methane and N <sub>2</sub> O are released during combustion. Emissions are calculated using emission factors for bioenergy taken from UK Government conversion factors for greenhouse gas reporting. This value is reported in CO <sub>2</sub> e.
Purchased renewable electricity	Purchased electricity where there is contractual evidence in place of renewably sourced electricity	<p>Where there is contractual evidence showing that the electricity used at a site is supported by electricity attribute certificates or unbundled certificates like RECs (North America), Guarantees of Origin (Europe) and I-RECs (other regions), GSK mark the electricity as 100% renewable within its reporting database.</p> <p>Retirement dates of certificates of origin do not align with the calendar year so these are not used as evidence at the time of reporting.</p> <p>Electricity consumption data is recorded as per details in this document, below.</p> <p>Data is reported into GSK's reporting database by sites in local units of energy and then converted to kWh.</p>
Purchased non-renewable electricity	Purchased electricity supplied from the grid with no market intervention to source renewable electricity	Where there is no contractual evidence showing that the electricity used at a site is renewable, GSK mark the electricity as 100% non-renewable within its reporting database. Data is reported into GSK's reporting database by sites in local units of energy and then converted to kWh.
On-site renewably generated electricity	Electricity generated on a GSK site from a renewable source	<p>On site renewable electricity data is from:</p> <ol style="list-style-type: none"> <li>on-site solar PV installations</li> <li>on-site wind turbines</li> <li>electricity generated in a combined heat and power plant that uses biogas as fuel.</li> </ol> <p>The biogas is generated in an on-site anaerobic digestion plant that treats fermentation waste. Consumption data is measured by site metering systems recorded on a monthly or bi-monthly basis by local facilities management teams, such as photo evidence, screen shots of meter reading or logged in Excel spreadsheets.</p>
Offsite renewably generated electricity	Electricity generated offsite from a renewable source with a direct connection to the site	Offsite solar energy generated adjacent to the facility but connected to the site for usage. This value is sourced under a Power Purchase Agreement (PPA).
Exported electricity	Electricity generated on a GSK site that is exported back to the grid	<p>This is the surplus electricity generated by on-site facilities, where an export meter exists.</p> <p>The power returned to the grid is measured via a separate fiscal meter; the utility provider issues an 'Export Statement' detailing the kWh exported and GSK raises an invoice. Import and export transactions are separate. For 2023 this was by two sites Ware R&amp;D from a gas-powered combined heat and power plant and the Irvine site from renewable sources that is returned to the grid. The energy exported was deducted from the total, but the gas emissions used in the CHP were included in the Scope 1 emissions total.</p>

Reported Metric and KPI	Definition and scope	Source and calculated methodology (converted to GWh for external reporting)
Renewable heat	Heat generated on a GSK site from combustion of biomass	One site in the network has a biomass boiler installed. Energy data is based on invoices from the supplier of biomass wood briquettes. Samples of the briquettes are tested periodically for moisture content, calorific value and ash content to confirm that the calorific value is ~3600 kcal per kg which is the conversion factor used in the data reporting platform.
	Hot water from on-site solar installations	Two sites in the network generate hot water from on-site solar installations.
Purchased heating and cooling	Purchased steam, compressed air, and chilled water	Purchased steam, compressed air and chilled water is supplied and invoiced from local utility providers.
Electricity used	Calculation	This is calculated from the total values of purchased renewable and non-renewable electricity renewably generated electricity on site using solar PV renewably generated electricity on site using Wind Turbines renewably generated electricity on site from combustion of biogas renewably generated electricity offsite from solar minus excess electricity generated on site from either combustion of fossil fuels or generated on site from renewable sources
Energy for operations	Calculation	This is calculated from the total values of – purchased natural gas and other fossil fuels – purchased renewable and non-renewable electricity – renewably generated electricity on site using solar PV – renewably generated electricity on site using Wind Turbines – renewably generated electricity on site from combustion of biogas minus excess electricity generated on site from either combustion of fossil fuels or generated on site from renewable sources as detailed above. Electricity that is generated from fossil fuel combustion on site such as from combined heat and power plants or from diesel generators is not included in this calculation to avoid double counting of the source fuel.
% Renewably sourced Electricity (RSE)	Calculation	This is calculated from the sum of purchased renewable electricity and electricity from on-site solar, wind or biogas divided by the sum of all purchased electricity and electricity from on-site solar, wind or biogas.
% Renewable Electricity (RE100)	Calculation	RE100 metric will be the sum of purchased renewable electricity plus on-site renewably generated electricity (e.g. solar, wind, biogas) subtracting renewable electricity exported back to the grid, as a proportion of the sum of total purchased electricity and all on-site generated electricity.  Purchased renewable electricity claims are aligned to RE100 Credible Claims guidance (2016) <sup>8</sup> , and are reported as a percentage.

## Biogenically derived emissions

Reported Metric and KPI	Definition and scope	Source and calculated methodology
Fermentation related emissions	CO <sub>2</sub> released during fermentation processes	CO <sub>2</sub> released during fermentation is calculated from measuring the concentration of CO <sub>2</sub> in off gas from the fermenter, the air flow, the duration of the fermentation batch and the number of batches manufactured during the year. The mass of CO <sub>2</sub> in kg is calculated on the basis that 44kg of CO <sub>2</sub> occupies 22.4m <sup>3</sup> at Standard Temperature and Pressure. This value is reported in CO <sub>2</sub> e.

<sup>8</sup> RE100 Making Credible Claims, [Technical Guidance & FAQs | RE100](#) last accessed 15 December 2025

## Scope 3 carbon emissions

GSK started reporting scope 3 emissions data in 2015 across all categories and screening each category for materiality and against spend data for completeness. The Scope 3 model uses financial and other data systems. Scope 3 emissions data reported is based on data from the prior year. GSK updates its Scope 3 emissions annually using a

hybrid model combining primary activity-based data and economic data from GSK's financial system. The scope 3 emissions model was developed, and quality assured by the Carbon Trust, with an annual quality check review. Scope 3 carbon emissions are measured in CO<sub>2</sub> equivalence. (CO<sub>2</sub>e)

Reported Metric and KPI	Definition and scope	Source and calculated methodology
1. Purchased goods and services	The extraction, production, and transportation of capital goods purchased or acquired by the reporting company in the reporting year	Emissions are calculated using a hybrid approach to evaluating the impacts of purchased goods and services, combining existing carbon footprint assessment data for raw materials where available with calculations using environmentally extended input-output (EEIO) emission factors for other areas of spend applied to data from GSK's financial systems. The carbon factors applied are from proprietary databases or completed footprint assessments.
2. Capital goods	The extraction, production, and transportation of capital goods purchased or acquired by the reporting company in the reporting year	Emissions are calculated using EEIO emission factors and data from GSK's financial systems.
3. Fuel and energy related activities	Upstream emissions of purchased fuels Upstream emissions of purchased electricity Transmission and distribution (T&D) losses	Emission factors for upstream emissions and T&D losses are applied to fuel and energy consumption data as reported in GSK's reporting database which detail energy type (fuel, purchased renewable and non-renewable electricity) in kWh by site and country.
4. Transportation and distribution (upstream)	The emissions from the transportation and distribution of products purchased or acquired by GSK in the reporting year in vehicles and facilities not owned or operated GSK, as well as other transportation and distribution services purchased by GSK in the reporting year (including both inbound and outbound logistics)	This category covers site to site logistics and outbound logistics to in-country distribution centres.  Emissions data from GSK's logistics providers based on movements are consolidated using the methodology from Eco-transit-world. This data is reconciled against data from GSK's financial system, and the remaining spend data related to upstream transportation and distribution is used to calculate emissions using EEIO environmentally extended input output factors.
5. Waste generated in operations	Disposal and treatment of waste generated in GSK's operations in the reporting year in facilities not owned or controlled by GSK	Emissions are calculated by applying UK Government conversion factors for greenhouse gas reporting for the route of recovery or disposal of each waste stream to the amounts of waste generated and reported by GSK sites.
6. Business travel	Transportation of employees for business-related activities during the reporting year (in vehicles not owned or operated by the reporting company).	Emissions for air travel are calculated by applying the International Air Transport Association (IATA) Recommended Practice – RP1726 emission methodology to individual air tickets accounting for distance (long haul, short haul) and class of air ticket (first, business, economy) and adding factors to take account of radiative forcing to maintain consistency with historical UK Government conversion factors for greenhouse gas reporting  Other impacts from business travel are calculated using EEIO emission factors and data from GSK's financial systems.
7. Employee commuting	Transportation of employees between their homes and their worksites during the reporting year. This excludes scope 1 related emissions from sales teams travelling to customer locations.	Emissions are calculated by applying a commuting model developed by the Carbon Trust that models different modes of transport and distances for staff to travel to a GSK Site. The model is applied to the number of Full Time Employees (FTE) and Complementary Workers (CW) by country.
8. Leased assets (upstream)	Emissions from the operation of assets leased by GSK in the reporting year and not included in Scope 1 & 2 emissions reports	Emissions of leased assets are covered by GSK's Scope 1 & 2 reporting (where above de-minimis threshold).
9. Transportation and distribution (downstream)	Emissions from transportation and distribution of products sold by GSK in the reporting year between GSK's operations and the end consumer in vehicles and facilities not owned or controlled by GSK	GSK have a model to estimate emissions based on product weights delivered to market and an estimate for the average distance travelled by road for products between an in-country distribution centre and the final retail outlet, pharmacy or clinic using UK Government conversion factors for greenhouse gas reporting.  GSK calculates indirect emissions for the refrigerated storage of vaccines in clinics prior to dispensing using a model developed by the Carbon Trust based on number of packs of vaccines supplied to markets in the reporting year.

Reported Metric and KPI	Definition and scope	Source and calculated methodology
10. Processing of sold products	Emissions from the processing of intermediate products sold in the reporting year by downstream companies to GSK	This category is not applicable for GSK products.
11. Use of sold products	<p>This category includes emissions from the use of goods and services sold by GSK in the reporting year.</p> <p>Two product categories are currently reported – direct emissions from the use of metered dose inhalers by patients (propellant-based inhalers) and indirect emissions from the chilled storage of doses of GSK vaccines in clinics prior to being dispensed</p>	<p>GSK calculate direct emissions of HFA134a gas released from the use of metered dose inhalers based on the fill weight of products leaving manufacturing sites for commercial supply, using data from GSK's financial systems. The Global Warming Potential (GWP) impact is calculated using 100-year lifetime emission factor for HFA134a as per the International Panel on Climate Change (IPCC) 4th Assessment Report. The assumption is that all propellant contained in the inhaler will be released to atmosphere.</p> <p>GSK report indirect emissions associated with dispensing vaccines in clinics based on a model developed by the Carbon Trust</p>
12. End of life	Waste disposal and treatment of products sold by GSK (in the reporting year) at the end of their life	GSK calculate emissions for end of life using the quantities of packaging materials purchased for products and UK Government conversion factors for greenhouse gas reporting.
13. Leased assets (downstream)	This category includes emissions from the operation of assets that are owned by GSK and leased to other entities in the reporting year that are not already included in scope 1 or scope 2.	GSK assessed this category and determined it is not material and therefore excluded from reporting in Scope 3 (as included in Scope 1&2 above the de-minimis threshold)
14. Franchises	This category includes emissions from the operation of franchises not included in Scope 1 or Scope 2	GSK do not operate franchises.
15. Investments	This category includes Scope 3 emissions associated with GSK's investments in the reporting year, not already included in Scope 1 or 2	GSK calculate emissions from investments applying EEIO emission factors to financial data for Investments in associates and joint ventures from GSK's financial system.

## Industrialisation of low GWP Metered Dose Inhalers

Reported Metric and KPI	Source and calculated methodology
Complete clinical studies to enable filing of low carbon version of <i>Ventolin MDI</i>	GSK monitors progress towards delivery of low carbon version of Ventolin MDI. Governance for this project is managed by existing R&D and commercial governance bodies using established governance and escalation routes. Completion is defined as achievement of the milestones set in the prior year for current year.

## Percent MTCO2 of 2030 carbon credits volume in Project Pipeline

Reported Metric and KPI	Definition and scope	Source and calculated methodology
% of carbon credits volume	Calculation	GSK has committed to an 80% absolute reduction in greenhouse gas emissions from a 2020 baseline, across all scopes and investment in nature-based solutions for the remaining 20% of our footprint by 2030. The volume of carbon credits secured in the portfolio is a percentage of GSK's planned emissions value in 2030. This value is calculated by taking credits available and planned for retirement against 2030 emissions, divided by 20% of GSK's total emissions in 2020 (the residual).



# Nature Related Reporting

## Water

GSK sites report water supplied to GSK from municipal supply, taken from groundwater wells located on sites or supplied in tankers by 3rd parties. Captured rainwater and recycled water are also measured and reported but not included in the 'total water supplied' calculation. GSK sites report wastewater sent to a municipal sewer, discharged to surface water after treatment on site, waste water used for irrigation, and wastewater used to recharge aquifers. Waste solvents and aqueous waste are reported in the waste category. Water data is entered in local units of measure by sites and converted into m3 for reporting purposes.

## Water used in regions of high-water stress

Under GSK's 2020 methodology, water stressed regions were identified in locations with a combined risk score of high and very high across three elements: Quantity, Quality and WASH (Water, Sanitisation and Hygiene) from the following tools: WRI Aqueduct Water Risk Atlas and WWF Water Risk Filter.

This methodology is applicable to the sites in scope for GSK's water neutrality target to 2030.

## Key Terms – Nature Related Reporting

Term	Definition
<b>Water neutral</b>	<p>We implement water neutrality at sites using three criteria:</p> <ol style="list-style-type: none"> <li>1. Achieving the Alliance for Water Stewardship Standard certification,</li> <li>2. Reducing water use by 20% and by replenishing water quantity in the basin equivalent to the site's 2030 footprint.</li> <li>3. Address shared water challenges in the basin through collective action, including access to clean water, hygiene and sanitation (WASH) services.</li> </ol> <p>We implement GSK water neutrality with key suppliers co-located in these water-stressed regions using three criteria:</p> <ol style="list-style-type: none"> <li>1. Practicing water stewardship as per GSK's standard,</li> <li>2. Committing to reduce water use or improve water efficiency and</li> <li>3. Contributing to basin wide water projects to achieve water replenishment or address shared water challenges.</li> </ol>
<b>Water Stress Risk</b>	Water stress is an imbalance between demand for water and available supply, which leads to deterioration of freshwater resources in terms on quantity and quality. Regions where water demand/ withdrawal is above 40% of available water are considered of high-water stress risk.
<b>Water drought risk</b>	Water drought is equated to low rain fall that leads to limited water availability.
<b>Water withdrawal/ abstraction</b>	Water influent into GSK's operations that resulted from abstraction from the environment i.e. Surface water, Tankers, underground water from wells. This does not include rainwater, recycled and reused water.
<b>Water Use</b>	All water influent into an operation from abstraction sources (municipal, tankers and groundwater) not including other sources (rain, reused and recycled).
<b>Water Consumption</b>	Water consumed is water that is not accounted in the effluents, when sites calculate the water balance, this is water that goes into products, evaporated and water that disappears due to leaks and waste.
<b>Non-Consumptive water</b>	The portion of water that passed through the operation but was not consumed and is returned to its source in the same condition; with the same quality in a way that it does not inflict pollution impacts. In the case of GSK rainwater recharged into the environment is considered non-consumptive water.
<b>Nature</b>	Refers to elements of the natural world both abiotic (water, air, soil, sea and land) and biotic (biodiversity).
<b>Biodiversity</b>	Refers to the biotic elements of the natural environment. It is the diversity of all living organisms: plants, animals, fungi, bacteria and viruses. These can be found in the environment in three main forms: Genes, Species and Ecosystems.
<b>Ecosystem</b>	Is a community of living organisms of various species and their interactions amongst themselves and with their natural environment. i.e. A forest, a wetland, a river.
<b>Habitat</b>	<p>It is defined as a small fraction of the ecosystem with homogeneous characteristics, i.e. a reedbed within a wetland ecosystem.</p> <p>The word "habitat" is often used (particularly in the UK) interchangeable with "ecosystem".</p>

Reported Metric and KPI	Definition and scope	Source and calculated methodology
Municipal	Fresh water supplied to GSK by a utility company through a mains supply	Municipal water is reported into GSK's reporting database by sites in local units of volume (m3, litre, imperial gallon, US gallon) and converted to m3 within the reporting database. Where utility invoices are not lined up directly to the start of a calendar month, these are recorded as invoiced. This method likely overestimates actual usage in some years and underestimates them in others but, over time, captures the related data.
Ground water	Fresh water taken from a borehole or well located on a GSK site	As no invoices are available for the supply of water from groundwater data is collected from on-site meter readings.
Tankers	Fresh water supplied to GSK in tankers by a utility company	Supply of water from tankers data is obtained from invoices provided by the supply company.
Total water use	All GSK sites above the reporting de minimis threshold are in scope, except for sites with a closure date announced	The total values of: Water from municipal supply Water from groundwater Water supplied in tankers Captured rainwater and recycled water are not included.
Recycled water	Fresh recycled water supplied to GSK by a third party	Fresh recycled water is obtained from invoices provided by the supply company.
Rainwater	Water collected onsite from rainwater	Rainwater is obtained from internal meter reading
Water use at high water risk sites	This is total water use (as calculated above) for sites identified by GSK as a highwater risk site	A region of high-water stress is defined by GSK as a region where there is a combined risk of high or very high across the three elements of Quantity, Quality and WASH (Water, Sanitisation and Hygiene) from the following tools: WRI Aqueduct Water Risk Atlas <sup>9</sup> and WWF Water Risk Filter <sup>10</sup> . GSK mapped the geographic location of its sites against outputs from these tools to identify sites located in regions of high-water stress. These sites are: – Karachi F268, Pakistan – Karachi West Wharf, Pakistan – Korangi, Pakistan – Nashik, India The site in Boudouaou, Algeria was classed as a high-water risk site under a previous methodology and is included in the list of high-water risk sites. Captured rainwater and recycled water are also measured and reported but not included in the 'total water supplied' calculation. Sites are assessed every three years.
Total Water Consumption for TNFD and SBTN	SBTN science-based methodology defines water consumption as the portion of water withdrawn from a source that it is not re-tuned to the source.	It is determined by Calculation Water consumed is Water withdrawn and brought into GSK sites (Ground water, tankers, municipal). Minus non-consumptive water, which is any water returned to its sourced without affecting its quality (i.e. effluent discharges to surface water and to aquifer recharge as long as the water quality is optimum in a way that does not inflict a pollution impact on the environment from GSK wastewater discharge).

<sup>9</sup> <https://www.wri.org/aqueduct> last accessed 16 December 2025

<sup>10</sup> <https://waterriskfilter.org/> last accessed 16 December 2025

Reported Metric and KPI	Definition and scope	Source and calculated methodology
Wastewater	<p>The total of wastewater sent to a municipal sewer, wastewater discharged to surface water after treatment on site, wastewater used for irrigation, wastewater used to recharge aquifers in accordance with local regulations.</p> <p>Liquid waste such as waste solvents that contain water are reported separately as waste.</p> <p>Sites are not mandated to report the following wastewater streams, in accordance with GRI Standard 303<sup>11</sup>.</p> <p>Untreated domestic sewage (e.g., offices, toilets, showers, and canteen) that discharge directly to a municipal sewer and is typically not metered.</p> <p>non-contaminated rainwater (storm waters)</p> <p>Evaporative losses</p>	<p>Wastewater data is reported by sites based on available information, including invoice data from utility companies and waste handlers, meter readings, or a calculation based on water use in the absence of a meter. In the absence of available data, sites may also provide a conservative data estimate by reporting that wastewater is equal to reported incoming water. In some cases, these values will be higher than incoming water due to the inclusion of 'bio sludge' or additional treatment of rainwater to mitigate API emissions.</p>

<sup>11</sup> GRI standard 303: Water and Effluents 2018' - <https://www.globalreporting.org/how-to-use-the-gri-standards/gri-standardsenglish-language/> (Please note: registration is needed to access the document) last accessed 16 December 2025

## GSK compliance with AMR Alliance and wastewater API limits

Reported Metric and KPI	Definition and scope	Source and calculated methodology
Metric 1 - Figure (%) from “% of GSK sites that are compliant with AMR Alliance and Wastewater API limits”	The scope is defined as GSK primary and secondary manufacturing sites and larger R&D sites that handle, manufacture, or use APIs, including antibiotics. All other sites are out of scope including API packaging sites, API intermediate sites, and sites using raw materials.	Annually all relevant sites calculate the concentration of API in wastewater discharges based on internally sourced assumption of API volumes, wastewater removal efficiencies, and water flow rates and record if it is below the Predicted No-Effect Concentration (PNEC) or that has been determined by GSK for APIs or by the AMR Industry Alliance discharge limits for antibiotics. Compliance is reported as the percentage of API sites in compliance with PNECs (or have an approved corrective and preventive actions (CAPA) in place) plus the percentage of Antibiotics sites in compliance with PNECs (or have an approved CAPA in place), divided by two. Previous iterations of the above paragraph stated that sites measure the concentration of APIs in wastewater discharges and compare this to a specified concentration limit. This has been changed to state that compliance for non-antibiotic APIs is calculated based on internally generated assumptions which are compared to an internally derived concentration limit. For antibiotics, the concentration is calculated based on internally generated assumptions which are compared to AMR Industry Alliance discharge limits.
Metric 2 - Figure (%) from “% of supplier locations used by GSK that are compliant with AMR Alliance and Wastewater API Limits”	The scope is defined as 3rd party sites (suppliers/CMO's that handle, manufacture, or use APIs, including antibiotics. All other supplier sites are out of scope including API packaging sites, API intermediate sites, and sites using raw materials.	A desktop assessment conducted by the supplier assesses concentration of API in wastewater discharges. Suppliers are assessed at least once based on internally sourced assumptions of API volumes, wastewater removal efficiencies, and water flow rates and record if it is below the Predicted No-Effect Concentration (PNEC) that has been determined by GSK for APIs or by the AMR Industry Alliance discharge limits for antibiotics. Suppliers demonstrate compliance via a PIE Calculator desktop assessment, analytical testing, upgrading wastewater treatment systems, incinerating waste and wastewater containing APIs, or having an approved CAPA. Compliance is reported as the percentage of API suppliers in compliance plus the percentage of Antibiotics suppliers in compliance, divided by two.
Metric- Combined % sites and supplier locations compliant with AMR alliance & waste-water API limits	The scope is defined as GSK primary and secondary manufacturing sites, 3rd party sites (suppliers/CMOs), and larger GSK R&D sites that handle, manufacture, or use APIs, including antibiotics. All other sites and suppliers are out of scope including API packaging sites, API intermediate sites, and sites using raw materials.	The combined figure is an average of Metric 1 and Metric 2.

## Water stewardship

Reported Metric and KPI	Definition and scope	Source and calculated methodology
Achieve good water stewardship at 100% of our sites by 2025	All GSK sites above the reporting de minimis threshold are in scope, except for sites with a closure date announced.	Measured through the metric: % Sites that practise good water stewardship. A site is considered to practise good water stewardship if they are compliant with the Water Stewardship section of GSK's Environmental Management and Sustainability Standard or have a CAPA in place.
20% of water reduction at all sites by 2030.	All GSK sites above the reporting de minimis threshold are in scope, except for sites with a closure date announced.	Measure as reduction % of water use 20% global average of sites in scope.

## Land

GSK's management of its impacts and dependencies on land takes place by two different programmes:

- Green spaces management for the delivery of biodiversity net gain at all sites.
- Sustainable sourcing programme to avoid and reduce land conversion resulting from our materials sourcing.

### Green Spaces Management

Reported Metric and KPI	Definition and scope	Source and calculated methodology
Area of land under management for Biodiversity Net Gain (BNG)	<p>The scope for this metric is the green spaces of sites that are above de minimis for reporting. The areas of land managed for BNG are defined in the site's land management plan. These do not cover the entirety of the green spaces at sites. The BNG management normally exclude areas that must be maintained clean of overgrown vegetation for health and safety reasons and other areas.</p>	<p>During the management planning developed for each site, ecologists identified the areas to be restored to ensure biodiversity improvement. Biodiversity net Gain at sites will be delivered through two types of management interventions: Habitat Creation and Habitat Restoration. Therefore:</p> <p>Total area of land managed for BNG (ha or m<sup>2</sup>) = Area of habitat creation + Area of habitat restoration.</p> <p><i>The area (number of hectares) designated for each type of management is determined by:</i></p> <p><i>Identification of the habitat and its condition by qualified ecologists. Spatial measurement of the area in question using GIS mapping.</i></p>

## Operational waste

GSK apply the term total waste to all routine operational hazardous and non-hazardous waste generated on and leaving

our sites. Non-routine waste such as construction and demolition or gardening waste are excluded.

Waste data is reported by sites by waste stream classifications developed by GSK and combined into aggregate categories such as total hazardous waste. Waste data is based on invoice data, data from waste transfer notes or calculations of circularity and is collected at site level. If primary data is not available, estimates are used based on weight data from our waste vendors, or

historical trends or other proxies. Where possible, waste data is entered in local units of measure by sites and converted into kg for reporting purposes using embedded conversion factors in the reporting system. Waste is reported in metric tonne, except for percent circular waste, which is reported as a percentage. Specific material flows that leave site for re-use and that are not classified as waste under applicable legislation (such as certain wooden pallets, drums, covered by an organised reuse system) are not used for reporting purposes.

### Waste reduction from supply chain by 2030

Reported Metric and KPI	Definition and scope	Source and calculated methodology
10% waste reduction from supply chain	<p>Focus on waste generated in the supply chain of our GSKs purchased goods and materials. Waste accumulates along the supply chains of purchased materials. We reduce waste in this supply chain by buying less materials from less resource intensive supply chains.</p>	<p>Baseline: Application of wastage rates (tonnes of waste along the supply chain per tonne of material purchased) to ERP derived purchased goods quantities. Performance: Application of waste reduction factors to activity data.</p>

Reported Metric and KPI	Definition and scope	Source and calculated methodology
Total waste	The sum of all hazardous and non-hazardous routine waste leaving sites	<p>Data on waste sent to a 3rd party is obtained from waste invoices and waste transfer notes. Where sites receive invoices from multiple waste handling companies, data is consolidated by waste stream, routine and non-routine waste, hazardous and non-hazardous waste and converted to kg.</p> <p>Where invoices do not provide the weight of individual consignments of waste, sites estimate the weight of an item.</p> <p>Waste is classified as hazardous or non-hazardous using the classification provided by the waste vendor in accordance with local legislation.</p> <p>Waste is classified as routine if it is waste from production (including trial and validation batches), packaging, maintenance, forward or reverse distribution (including product recalls), office and other ancillary facility operations. Routine Waste is any material that leaves the site as a residue of the typical GSK day to day operational activities (referred to as Routine).</p> <p>Waste is classified as non-routine if it is from construction and demolition waste, gardening waste, or from decommissioning a building or area.</p>
Total circular waste	Calculation	<p>GSK classifies waste by its disposal or recovery route as sent to the waste receiving company. Circular waste is the sum of any routine waste (as defined above) that is sent to one of the following routes of processing.</p> <p>Composting or Anaerobic Digestion</p> <p>Land treatment resulting in benefit to agriculture or ecological improvement such as for compost.</p> <p>Off-Site Reuse of non-solvent waste</p> <p>Off-Site Solvent reclamation/regeneration</p> <p>Oil re-refining or other reuses of oil.</p> <p>Recycling/reclamation of materials</p>
Total non-circular waste	Calculation	<p>Non-Circular waste is the sum of any routine waste (as defined above) that is sent to one of the following routes of processing.</p> <p>Land treatment with no benefit.</p> <p>Landfill</p> <p>Off-site wastewater treatment plant for specialist treatment prior to sending wastewater to a wastewater treatment plant.</p> <p>Off-site for use principally as a fuel or other means to generate energy.</p> <p>Off-Site incineration without energy recovery</p> <p>Permanent storage</p> <p>Other routes of disposal on a case-by-case basis</p>
Total waste to landfill	Calculation	<p>Waste to landfill is the sum of all waste sent to landfill. This is a subset of total waste, and total non-circular waste. For reporting purposes when materials and waste leave a GSK site, the next site that receives the material should be the point at which the disposal/recovery method should be identified and recorded. This means that GSK report waste sent to incineration off site as the destination after it has been accepted by the waste processor. GSK report ash waste sent to landfill for any waste incinerated on site.</p> <p>Local regulations may mandate that a GSK site must send a waste stream to landfill or if landfill as the best environmental option (e.g., for asbestos disposal). For sites that are required to send material to landfill for local regulations, GSK still consider that status as Zero Waste to Landfill.</p>

Reported Metric and KPI	Definition and scope	Source and calculated methodology
Total waste incinerated	Calculation	Total waste incinerated is the sum of any hazardous and non-hazardous routine waste (as defined above) that is sent to one of the following routes of processing. 1. Off-site for use principally as a fuel or other means to generate energy. 2. Off-Site incineration without energy recovery
% Circular waste	Calculation	This is calculation from the total circular waste divided by the total waste expressed as a percentage.
Waste otherwise disposed	Aqueous waste sent for specialist treatment offsite	Aqueous waste sent for specialist treatment offsite is the sum of any routine waste (as defined above) that is sent to off-site wastewater treatment plant for specialist treatment prior to sending wastewater to a wastewater treatment plant.

## Sustainable sourcing

For paper packaging and palm oil derivatives, invoice data has a 1-month lag and management monitoring requires two weeks, so year-end reporting will cover January to October plus a two-month estimate based on prior month tonnages and certification statuses.

### Environmental impact reduction for our products and packaging by 2030

Reported Metric and KPI	Definition and scope	Source and calculated methodology
25% environmental impact reduction (CO2e as lead metric)	Aggregated carbon reduction, in %, delivered on the 12 products including packaging that are anticipated to be the main drivers of the 2030 company carbon footprint if no eco-design action was taken.	LCA (ISO 14040 and 14044)

Reported Metric and KPI	Definition and scope	Source and calculated methodology
% of paper and palm oil certified	Calculation For Paper Packaging, Certified is defined as sourced from tier-1 and tier-2 suppliers covered by an FSC (Forest Stewardship Council) or PEFC (Programme for Endorsement of Forest Certification) Chain of Custody Certification OR material with 50% or greater recycled content.	Total volume of paper packaging material meeting GSK's definition of 'Paper Packaging End of Year Reporting Calculation
	For Paper Packaging materials (Cartons, Leaflets, Labels, and Corrugates) purchased at a category and site level are in scope for this metric.	$= \frac{\text{Total paper packaging tonnage purchased (Jan to Oct actuals + Nov, Dec extrapolation of October data)}}{\text{Total paper packaging tonnage purchased (Jan to Oct actuals + Nov, Dec extrapolation of October data)}} \times \text{through suppliers qualified as certified sources at end of October}$
		Paper Packaging Quarterly Reporting Calculation
		$= \frac{\text{Total paper packaging tonnage purchased through suppliers qualified as certified sources at end of quarter}}{\text{Total paper packaging tonnage purchased in quarter}}$
	For Palm Oil, Certified is defined as material certified under RSPO (Roundtable on Sustainable Palm Oil) Identity Preserved, Segregated, Mass Balance or Book & Claim credits	Acceptable evidence for demonstrating meeting GSK's definition of certified / recycled paper packaging includes:
	The list of Palm Oil derivatives in scope can be referred from metrics definition document.	<ol style="list-style-type: none"> <li>1) FSC and or PEFC Certification numbers for relevant paper/pulp mills and converters/printers that have been checked against the FSC Database and/or PEFC database to be valid at time of reporting and within their expiration date.</li> <li>2) For paper packaging material containing greater than 50% recycled content, evidence of recycled content through certificate of analysis, specification documents or an official confirmation on letter-headed paper shared directly with the Purchaser of Paper Packaging Material.</li> <li>3) For paper packaging suppliers undergoing certification or renewal of certification at time of quarterly or end of year reporting period, evidence that certification process is underway with certification audit booked and an expected completion date is acceptable to qualify the supplier as provisionally certified. The status is then updated once the certification audit results are received from the supplier.</li> </ol>
	Any new Palm Oil derivatives identified after the baseline for the year has been agreed will be out of scope for the metric but will be integrated into the next year's delivery.	
		For end of year reporting on Palm Oil certified material, GSK will track the % of the total tonnage of Palm Oil derivatives purchases made between Jan-Oct that were RSPO certified under Mass Balance, Segregated or Identity Preserved supply chain models. In the event of purchase of any non RSPO certified Palm Oil tonnages, GSK will purchase the equivalent number of RSPO Book and Claim Credits to reach 100% Palm Oil RSPO Certified.
		Palm Oil End of Year Reporting Calculation
		$= \frac{\text{Total Palm Oil tonnage (Jan to Oct actuals + Nov, Dec extrapolation of October data) purchased as RSPO Certified Mass Balance, Identity Preserved, Segregated + Total RSPO Credits Purchased}}{\text{Total Palm Oil Tonnage (Jan to Oct actuals + Nov, Dec extrapolation of October data)}}$
		Palm Oil Quarterly Reporting Calculation
		$= \frac{\text{Total Palm Oil tonnage purchased in quarter as RSPO Certified under Mass Balance, Identity Preserved or Segregated}}{\text{Total Palm Oil Tonnage purchased in quarter}}$
		Acceptable evidence for demonstrating Palm Oil derivatives meeting GSK's definition of certified Palm Oil includes:



Reported Metric and KPI	Definition and scope	Source and calculated methodology
		<ol style="list-style-type: none"> <li>1) RSPO Certification number covering the material supplied to GSK with indication it is either Mass Balance, Identity Preserved or Segregated supply chain model. RSPO certification number for the supplying entity should also be verified as valid and in date on the RSPO Database.</li> <li>2) Request supplier to provide an RSPO material certification number with each delivery. Certification numbers can be captured on Invoices, Delivery Notes, Labels, Certificate of Analysis or shared directly with the Purchaser of Palm Oil Derivatives. Evidence should be retained for 3-years.</li> <li>3) Evidence to confirm non palm oil derived material- Certificate of analysis/Technical specification document/ Letter head confirmation of no palm oil content from supplier/ email confirmation from GSK Procurement lead.</li> <li>4) Evidence of purchase of RSPO Book and Claim Credits through RSPO Prisma platform through credit certificates matching the number of tonnes of uncertified tonnage.</li> <li>5) A letter-headed declaration from supplier to supply 100% RSPO Certified materials to GSK</li> </ol>

### Suspended/Terminated Certificate

In the event of a supplier's certificate being suspended or terminated by global certification bodies - FSC, PEFC, RSPO. GSK will follow a consistent process to manage these cases and implement a remediation plan. For further details on certification suspension, termination, and re-certification requirements, the standards can be referred to on respective websites for FSC, RSPO and PEFC.

### Remediation Status and Timelines

- **Suspension or Termination:** Suppliers whose certifications are suspended or terminated will be moved into "remediation" status for a period of 6 months from the date of the suspension or termination.
- **Evidence Submission:** The supplier should confirm to GSK the reason for suspension/termination and the corrective action plan and timelines for returning to certified status.

- **Zero Tolerance:** If FSC certification has been suspended or terminated due to credible evidence of illegal logging, deforestation of natural forests after 31 December 2020, serious violations of human or labor rights or fraudulent or misleading use of FSC claims, GSK will suspend new business and seek alternative sourcing within a timeline that does not impact security of supply.
- **Provisional Certified Source Status:** During the remediation period, associated tonnage will be considered as "provisionally certified source/material" and counted towards the metric.
- **Re-certification:** If the supplier successfully completes the remediation process and their certification status is changed to "Valid/Active" in the certification body's portal, GSK will update their certified source status in its database accordingly.
- **Non-Certified Status:** If the supplier fails to re-certify within the 6-month remediation period, they will be moved to "non-certified source" status.
- **Impact Review:** GSK will review any impact on certification metrics and end-of-year numbers in February, once the full dataset for the year becomes available, to confirm any significant variances.

## Appendix 1: Reported Metric Calculation Methodology

Reported Metric and KPI	Definition and scope	Source and calculated methodology (Reported in CO <sub>2</sub> e)
On-site fuel use	Scope 1 emissions from combustion of fossil fuels on site	Fuel consumption data is converted to units of CO <sub>2</sub> e using carbon emission factors taken from UK Government conversion factors for greenhouse gas reporting. Sources are invoices, meter readings, on-site systems or proxy data as detailed in each category for site fuel.
Sales force vehicles	Scope 1 emissions for the vehicles leased for the sales force	CO <sub>2</sub> e emissions for vehicles used by the sale force are based on data from GSK's fleet leasing companies, and static country database which consist of details of leased and purchased vehicles. GSK collects data from fleet leasing providers' data systems and static country database (through direct feedback) to obtain a vehicle level report that contains annual contracted distance data for each vehicle and CO <sub>2</sub> e emissions data as published by vehicle manufacturers. Distance data is converted to km from miles in order to calculate total CO <sub>2</sub> e emissions for the calendar year. Vehicle data is consolidated across all vehicle providers to calculate CO <sub>2</sub> e emissions.  In the case of vehicles for which annual contracted distance, contractual termination duration, CO <sub>2</sub> emissions data are missing, fixed figures based on engine type of the vehicle (for CO <sub>2</sub> emissions) and standard fleet policy of GSK (for annual contracted distance, contractual termination duration) are used.
Propellant emissions during manufacture of inhalers	Scope 1 emissions for the fugitive emissions of HFA134a gas released during manufacturing of GSK's Metered Dose Inhalers	Fugitive emissions of HFA134a are based on an inventory reconciliation methodology at the three sites where GSK's inhalers are manufactured and includes the amount of HFA134a: <ul style="list-style-type: none"> <li>- Delivered to site as measured on weighbridges</li> <li>- Leaving site in finished product</li> <li>- Captured as waste</li> <li>- And calculating the fugitive releases from quality testing procedures for the various products</li> </ul>
Refrigerant gas losses	Scope 1 emissions of refrigerant from ancillary equipment on GSK sites that contain >1kg of refrigerant	GSK sites maintain an inventory of equipment containing >1kg of refrigerants detailing the amount and type of refrigerant used. This is updated annually.  Fugitive losses are measured by the amount of refrigerant that is required to top up ancillary equipment during regulatory inspections or following the identification of a leak.
Electricity (market-based emissions)	Scope 2 carbon emissions from electricity reflecting the sourcing choice that GSK have made for the purchased Electricity	The market-based method derives emissions factors from contractual instruments, which include any type of contract between two parties for the sale and purchase of energy bundled with attributes about the energy generation, or for unbundled attribute claims. Where these are in place, GSK applies an emission factor of zero for the calendar year in line with the GHG Protocols. GSK applies factors sourced from the International Energy Agency for all other sites in the reporting boundary and not the residual mix factors to these sites as residual mix factors are not available for all markets where GSK operates.
Electricity (location-based emissions)	Scope 2 carbon emissions from electricity reflecting national grid averages	The location-based method involves using an average emission factor that relates to the local grid from which electricity is drawn. Data from the IEA database. From 2021 onwards, GSK only had manufacturing operations in Quebec province, Canada. The average national grid factor is not representative of the predominantly hydroelectric power mix in Quebec province, GSK use as a location factor for this site taken from the Canadian National Inventory 2022.
Purchased heating and cooling	Scope 2 carbon emissions from purchased heating and cooling	Scope 2 carbon emissions are for purchased steam and are calculated by converting reported energy in kWh to CO <sub>2</sub> e using carbon emission factors from UK Government conversion factors for greenhouse gas reporting
Scope 1 & 2 GHG emissions intensity from energy per £m revenue	Intensity ratio of GSK total Scope 1 & 2 emissions from energy using market-based accounting for the calendar year approach per £ revenue for the calendar year	The aggregate total Scope 1 & 2 emissions from energy reported by GSK divided by GSK total revenue as reported in the end of year financial statements. This value is reported in CO <sub>2</sub> e per £.

Reported Metric and KPI	Definition and scope	Source and calculated methodology (Reported in CO <sub>2</sub> e)
Scope 1 & 2 GHG emissions intensity from energy per FTE	Intensity ratio of GSK total Scope 1 & 2 emissions from energy using market-based accounting for the calendar year approach per FTE for the calendar year	The aggregate total Scope 1 & 2 emissions from energy reported by GSK divided by GSK FTE sourced from Workday as reported in the company Annual Report. This value is reported in CO <sub>2</sub> e per FTE.

## Appendix 2: Scope 1 and 2 Emission Factors

### Scope 1 Emission Factors

Year	Scope 1 fuels	Scope 1 HFCs from inhalers and refrigerants	Scope 1 sales force emissions	Scope 1 solvent waste to energy
2021	UK government conversion factors 2020	IPCC 4th Assessment report	Individual vehicle data provided by Fleet providers	UK conversion factors 2022 based on bioethanol as proxy
2022	UK government conversion factors 2021	IPCC 4th Assessment report	Individual vehicle data provided by Fleet providers	UK conversion factors 2022 based on bioethanol as proxy
2023	UK government conversion factors 2022	IPCC 4th Assessment report	Individual vehicle data provided by Fleet providers	UK conversion factors 2022 based on bioethanol as proxy
2024	UK government conversion factors 2023	IPCC 4th Assessment report	Individual vehicle data provided by Fleet providers	UK conversion factors 2022 based on bioethanol as proxy
2025	UK government conversion factors 2024	IPCC 4th Assessment report	Individual vehicle data provided by Fleet providers	UK conversion factors 2024 based on bioethanol as proxy

### Scope 2 Emission Factors

Year	Scope 2 imported electricity location factor	Scope 2 imported electricity market factor	Scope 2 imported steam, chilled water & compressed air	Scope 2 imported chilled water and compressed air
2021	IEA 2022 emission factor set	GSK replace location emission factors with a market factor when there is evidence of the purchase of Energy Attribution certificates	UK government conversion factors 2022	Uses imported steam factor as proxy
2022	IEA 2022 emission factor set		UK government conversion factors 2022	Uses imported steam factor as proxy
2023	IEA 2022 emission factor set		UK government conversion factors 2022	Uses imported steam factor as proxy
2024	IEA 2023 emission factor set		UK government conversion factors 2023	Uses imported steam factor as proxy
2025	IEA 2024 emission factor set		UK Government GHG conversion factors 2024	Uses imported steam factor as proxy

Outside of Scope 1 & 2 emissions		CO <sub>2</sub> from fermentation
2021		Calculated based on CO <sub>2</sub> concentration in fermentation off gas.
2022		
2023		
2024		
2025		

## Appendix 3: Reporting and Calculation Exceptions

### General exceptions are:

- GSK do not use residual mix emission factors for Scope 2 market-based emissions for sites not purchasing renewable electricity as these factors are not available for all countries where GSK has operations that fall within the reporting boundary.
- Scope 3 emissions for upstream transportation between tier 1 suppliers and GSK.
- (R&D) reports separately due to the complexity of legacy billing and metering set up.

### The following are exclusions and additional detail for energy reporting exceptions:

- All mobile, back-up, and temporary equipment are excluded from reporting (either direct or third party), unless, where fuel is taken from central bulk fuel storage to power this equipment, then this use will be captured through the bulk fuel purchase data.
- Where GSK are directly using fuel for back-up installations, where the primary systems are down, this should be reported or estimated in lieu of the energy that would have been used in the primary system it is replacing (such as back-up power generation, or back-up chillers).
- All portable gas bottles are excluded from reporting. Fixed gas bottle/tank installations for operational use must report gas recharges and supported with an invoice or marked as an estimate.
- Fuel used for onsite transport only is excluded (e.g., forklifts)
- All other fuel and energy use should be reported, or an explanation provided for non-reporting.
- CO2 emissions from on-site waste treatment processes are excluded on grounds of materiality. This data historically has accounted for approximately 0.01% of total Scope 1 & 2 market emissions.
- Purchased non-renewable electricity: Egyptian site invoices are labelled one month in arrears – i.e., January use appears as February on the invoice.
- Canada National Inventory Report for Quebec region emission factor for electricity generation for the St Foy Vaccine manufacturing site<sup>12</sup> & Vendor provided emissions factors for purchased steam supplied to the Dresden and Evreux manufacturing site supported by evidence.
- Purchased heating and cooling: the Evreux and Dresden sites have provided evidence of how the steam that is purchased for these sites is generated along with an emissions factor from the vendor that has been embedded into the database.

### Water:

- UM Biopharm site excludes water use from sprinkler system testing.
- The GSK site in Saudi Arabia is not considered to be a highwater stress site owing to the availability of water from desalination plants.

### Wastewater:

- Barnard Castle and Montrose sites receives invoices for wastewater in metric tonne. This is converted to m3 using a conversion factor of one.
- Egyptian sites report an estimate based on the water supplied (via invoice) and the cost of sewage treatment (via invoice) to calculate the mass of wastewater.
- Conversion factors are based on the density of water is 1 g/cm3. 1 m3 = 1,000 kg, 1 litre = 1 kg.

### Total water use

- There are some sites that consist of multiple buildings across more than 1 campuses (Sub sites, on top of main site). GSK may only use a part/portion of these for business purpose. These sites would have water meters entering the site that need to be recorded and reported.

<sup>12</sup> Canada National Inventory report 2021, section 3, Table A13–6

Electricity

Generation and GHG Emission Details for Quebec, electricity generation intensity p65 <https://unfccc.int/documents/271493> Last accessed 16 December 2025